Top

Published in:

01-06-2009

Biology of TNFα and IL-10, and their imbalance in heart failure

Authors: Kuljeet Kaur, Sanjiv Dhingra, Jan Slezak, Anita K. Sharma, Anju Bajaj, Pawan K. Singal

Published in: Heart Failure Reviews | Issue 2/2009

Abstract

Our understanding of the multiple in vivo functions of the proinflammatory cytokine, tumor necrosis factor (TNFα), is advancing at a rapid pace. In addition to its antitumor effects, overproduction of TNFα provokes tissue injury and organ failure. TNFα has also been shown to be cardiodepressent and responsible for various cardiovascular complications. It appears that still much needs to be learned for a full comprehension of the role of TNFα in heart biology. Another cytokine, interleukin-10 (IL-10), has been shown to have anti-inflammatory properties. It is suggested to counterbalance many adverse effects of TNFα. IL-10 suppresses the production of TNFα and many other proinflammatory cytokines. TNFα-induced oxidative stress is also known to be mitigated by IL-10. Moreover, improvement in cardiac function after treatment with various drugs is also shown to be associated with an increase in IL-10 content. Based on the data reviewed in here, it is suggested that an optimal balance between IL-10 and TNFα may be a new therapeutic strategy for a healthier heart.

Kaur K, Sharma AK, Singal PK (2006) Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 291:H106–H113. doi:10.1152/ajpheart.01327.2005 PubMed

Dhingra S, Sharma AK, Singla DK, Singal PK (2007) p38 and ERK 1/2 MAPkinases mediate interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 293:H3524–H3531. doi:10.1152/ajpheart.00919.2007 PubMed

Kaur K, Sharma AK, Dhingra S, Singal PK (2006) Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol 41:1023–1030. doi:10.1016/j.yjmcc.2006.08.005 PubMed

Pulkki KJ (1997) Cytokines and cardiomyocyte death. Ann Med 29:339–343. doi:10.3109/07853899708999358 PubMed

Yao YY, Yin H, Shen B, Chao L, Chao J (2007) Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail 13:588–596. doi:10.1016/j.cardfail.2007.04.009 PubMed

Mann DL, Young JB (1994) Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105:897–904. doi:10.1378/chest.105.3.897 PubMed

Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243–249. doi:10.1016/S1071-9164(96)80047-9 PubMed

Langer SE, Scheer JF (1995) Solved—the riddle of illness. Keats Pub, USA

Deidier A (1725) Dissertation Medecinal et Chirurgical sur les Tumeurs, Paris

10.

Kolmel K, Pfahlberg A, Mastrangelo G et al (1999) Infections and melanoma risk: results of a multicentre EORTC case-study. Melanoma Res 9:511–519PubMed

11.

Busch W (1868) Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5:137

12.

Bruns P (1888) Die Heilwirkung des Erysipelas auf Geschwülste. Beitr Klin Chir 3:443

13.

Lassar O (1891) Zur Erysipelimpfung. Dtsch Med Wochenschr 17:889CrossRef

14.

Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105:487–511. doi:10.1097/00000441-189305000-00001

15.

Shear HJ, Marks ES (1962) Measuring self-confining behaviour patterns. J Clin Psychol 18:26–28. doi:10.1002/1097-4679(196201)18:1<26::AID-JCLP2270180107>3.0.CO;2-SPubMed

16.

Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670. doi:10.1073/pnas.72.9.3666 PubMed

17.

Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN (1985) Human tumor necrosis factor: production, purification and characterization. J Biol Chem 260:2345–2354PubMed

18.

Matthews N (1978) Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer 38:310–315PubMed

19.

Fiers W (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285:199–221. doi:10.1016/0014-5793(91)80803-B PubMed

20.

Spiegelman BM, Hotamisligil GS (1993) Through thick and thin: wasting, obesity, and TNF alpha. Cell 73:625–627. doi:10.1016/0092-8674(93)90243-J PubMed

21.

Fiers W, Beyaert R, Brouckaert P et al (1987) Tumor necrosis factor: a potential antitumor agent? J Interferon Res 7:627–634PubMed

22.

Loetscher H, Pan YC, Lahm HW et al (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351–359. doi:10.1016/0092-8674(90)90815-V PubMed

23.

Smith CA, Davis T, Anderson D et al (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019–1023. doi:10.1126/science.2160731 PubMed

24.

Vandenabeele P, Declercq W, Beyaert R, Fiers W (1995) Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5:392–399. doi:10.1016/S0962-8924(00)89088-1 PubMed

25.

Grell M, Douni E, Wajant H et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793–802. doi:10.1016/0092-8674(95)90192-2 PubMed

26.

Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 95:570–575. doi:10.1073/pnas.95.2.570 PubMed

27.

Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL (1995) Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92:1487–1493PubMed

28.

Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452. doi:10.1146/annurev.iy.10.040192.002211 PubMed

29.

Beutler B, Cerami A (1988) Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 57:505–518. doi:10.1146/annurev.bi.57.070188.002445 PubMed

30.

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501. doi:10.1016/S0092-8674(01)00237-9 PubMed

31.

Loetscher H, Gentz R, Zulauf M et al (1991) Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem 266:18324–18329PubMed

32.

Wajant H, Henkler F, Scheurich P (2001) The TNF-receptor-associated factor family: scaffold molecules for cytokinereceptors, kinases and their regulators. Cell Signal 13:389–400. doi:10.1016/S0898-6568(01)00160-7 PubMed

33.

Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845–853. doi:10.1016/0092-8674(93)90464-2 PubMed

34.

Hsu H, Xiong J, Goeddel DV (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:495–504. doi:10.1016/0092-8674(95)90070-5 PubMed

35.

Stanger BZ, Leder P, Lee TH, Kim E, Seed B (1995) RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81:513–523. doi:10.1016/0092-8674(95)90072-1 PubMed

36.

Duan H, Dixit VM (1997) RAIDD is a new ‘death’ adaptor molecule. Nature 385:86–89. doi:10.1038/385086a0 PubMed

37.

Enari M, Talanian RV, Wong WW, Nagata S (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380:723–726. doi:10.1038/380723a0 PubMed

38.

Vanden Berghe W, Plaisance S, Boone E et al (1998) p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273:3285–3290. doi:10.1074/jbc.273.6.3285 PubMed

39.

Chang DJ, Ringold GM, Heller RA (1992) Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-alpha is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun 188:538–546. doi:10.1016/0006-291X(92)91089-9 PubMed

40.

Kapadia S, Dibbs Z, Kurrelmeyer K et al (1998) The role of cytokines in the failing human heart. Cardiol Clin 16:645–656. doi:10.1016/S0733-8651(05)70041-2 PubMed

41.

Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930–933. doi:10.1016/S0140-6736(00)02690-8 PubMed

42.

Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986–2989PubMed

43.

Satoh M, Nakamura M, Tamura G et al (1997) Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29:716–724. doi:10.1016/S0735-1097(96)00567-0 PubMed

44.

Torre-Amione G, Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704–711PubMed

45.

Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B (1992) The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90:693–698. doi:10.1172/JCI115939 PubMed

46.

Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL (1995) Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96:1042–1052. doi:10.1172/JCI118090 PubMed

47.

Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL (1997) Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 81:187–195PubMed

48.

Yue P, Massie BM, Simpson PC, Long CS (1998) Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 275:H250–H258PubMed

49.

Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH (1998) Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfusedmodel of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65:439–443. doi:10.1016/S0003-4975(97)01297-6 PubMed

50.

Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206. doi:10.1016/0735-1097(95)00589-7 PubMed

51.

Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060–3067PubMed

52.

Ferrari R (1998) Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res 37:554–559. doi:10.1016/S0008-6363(97)00309-X PubMed

53.

MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S (1997) Circulating interleukin-6 in severe heart failure. Am J Cardiol 79:1128–1131. doi:10.1016/S0002-9149(96)00063-X PubMed

54.

Testa M, Yeh M, Lee P et al (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28:964–971. doi:10.1016/S0735-1097(96)00268-9 PubMed

55.

Torre-Amione G, Stetson SJ, Youker KA et al (1999) Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 100:1189–1193PubMed

56.

Heard SO, Perkins MW, Fink MP (1992) Tumor necrosis factor-alpha causes myocardial depression in guinea pigs. Crit Care Med 20:523–527. doi:10.1097/00003246-199204000-00015 PubMed

57.

Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS (1992) Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest 90:389–398. doi:10.1172/JCI115873 PubMed

58.

Eichenholz PW, Eichacker PQ, Hoffman WD et al (1992) Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 263:H668–H675PubMed

59.

Eichacker PQ, Hoffman WD, Farese A et al (1991) TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J Appl Physiol 71:1979–1989PubMed

60.

Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387–389. doi:10.1126/science.1631560 PubMed

61.

Murray DR, Freeman GL (1996) Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 78:154–160PubMed

62.

Bozkurt B, Kribbs SB, Clubb FJ Jr et al (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382–1391PubMed

63.

Kubota T, McTiernan CF, Frye CS et al (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627–635PubMed

64.

Nakamura K, Fushimi K, Kouchi H et al (1998) Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98:794–799PubMed

65.

Suematsu N, Tsutsui H, Wen J et al (2003) Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107:1418–1423. doi:10.1161/01.CIR.0000055318.09997.1F PubMed

66.

Bianchi P, Kunduzova O, Masini E et al (2005) Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 22:3297–3305. doi:10.1161/CIRCULATIONAHA.104.528133

67.

Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Oberley TD (2004) Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 32:536–547. doi:10.1080/01926230490502601 PubMed

68.

Vlessis AA, Muller P, Bartos D, Trunkey D (1991) Mechanism of peroxide-induced cellular injury in cultured adult cardiac myocytes. FASEB J 5:2600–2605PubMed

69.

Li YY, Feng YQ, Kadokami T et al (2000) Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 97:12746–12751. doi:10.1073/pnas.97.23.12746 PubMed

70.

Shen J, O’Brein D, Yi X (2006) Matrix metalloproteinases-2 contributes to tumor necrosis factor alpha induced apoptosis in cultured rat cardiac myocytes. Biochem Biophys Res Commun 347:1011–1120. doi:10.1016/j.bbrc.2006.07.002 PubMed

71.

Krown KA, Page MT, Nguyen C et al (1996) Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 15:2854–2865. doi:10.1172/JCI119114

72.

Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT (1995) Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27:1281–1292. doi:10.1016/S0022-2828(05)82390-9 PubMed

73.

Natanson C, Eichenholz PW, Danner RL et al (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823–832. doi:10.1084/jem.169.3.823 PubMed

74.

Castagnoli C, Stella M, Berthod C, Magliacani G, Richiardi PM (1993) TNF production and hypertrophic scarring. Cell Immunol 147:51–563. doi:10.1006/cimm.1993.1047 PubMed

75.

Rawdanowicz TJ, Hampton AL, Nagase H, Woolley DE, Salamonsen LA (1994) Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 79:530–536. doi:10.1210/jc.79.2.530 PubMed

76.

Gottschall PE, Yu X (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64:1513–1520PubMedCrossRef

77.

Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602. doi:10.1161/01.CIR.0000124490.27666.B2 PubMed

78.

Bozkurt B, Torre-Amione G, Warren MS et al (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044–1047PubMed

79.

Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P (1998) Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351:1091–1093. doi:10.1016/S0140-6736(97)09338-0 PubMed

80.

Mohler KM, Sleath PR, Fitzner JN et al (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218–220. doi:10.1038/370218a0 PubMed

81.

Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–1680. doi:10.1084/jem.177.6.1675 PubMed

82.

Parrillo JE, Cunnion RE, Epstein SE et al (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061–1068PubMed

83.

Berthonneche C, Sulpice T, Boucher F et al (2004) New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 287:H340–H350. doi:10.1152/ajpheart.01210.2003 PubMed

84.

Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol (Baltimore, Md.: 1950) 147:3815–3822

85.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW et al (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (Baltimore, Md.: 1950) 146:3444–3451

86.

Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765. doi:10.1146/annurev.immunol.19.1.683 PubMed

87.

Wang P, Wu P, Siegel MI, Egan RW, Billah MM (1995) Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558–9563. doi:10.1074/jbc.270.16.9558 PubMed

88.

Levens JM, Gordon J, Gregory CD (2000) Micro-environmental factors in the survival of human B-lymphoma cells. Cell Death Differ 7:59–69. doi:10.1038/sj.cdd.4400636 PubMed

89.

Moore KW, Vieira P, Fiorentino DF et al (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230–1234. doi:10.1126/science.2161559 PubMed

90.

Howard M, O’Garra A (1992) Biological properties of interleukin 10. Immunol Today 13:198–200. doi:10.1016/0167-5699(92)90153-X PubMed

91.

Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H (2002) The interleukin-10 family of cytokines. Trends Immunol 23:89–96. doi:10.1016/S1471-4906(01)02149-4 PubMed

92.

Platzer C, Volk HD, Platzer M (1994) 5′ noncoding sequence of human IL-10 gene obtained by oligo-cassete PCR walking. DNA Seq 4:399–401. doi:10.3109/10425179409010188 PubMed

93.

Platzer C, Docke WD, Volk HD, Prosch S (2000) Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells. J Neuroimmunol 105:31–38. doi:10.1016/S0165-5728(00)00205-8 PubMed

94.

Barsig J, Kusters S, Vogt K, Volk HD, Tiegs G, Wendel A (1995) Lipopolysaccharide-induced IL-10 in mice: role of endogenous TNF-alpha. Eur J Immunol 25:2888–2893. doi:10.1002/eji.1830251027 PubMed

95.

Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD (1996) Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 26:1580–1586. doi:10.1002/eji.1830260726 PubMed

96.

Ma W, Lim W, Gee K et al (2001) The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276:13664–13674PubMed

97.

Walter MR (2002) Strucure of interleukin-10/interleukin-10R1 complex: a paradigm for class 2 cytokine activation. Immunol Res 26:303–308. doi:10.1385/IR:26:1-3:303 PubMed

98.

Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA (1995) Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol (Baltimore, Md.: 1950) 154:3454–3460

99.

Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell RN (1999) Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo. Am J Pathol 155:1929–1939PubMed

100.

vander Poll T, Marchant A, Buurman WA et al (1995) Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 155:5397–5401

101.

Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL (1995) Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol (Baltimore, Md.: 1950) 155:2222–2229

102.

Lang R, Rutschman RL, Greaves DR, Murray PJ (2002) Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol (Baltimore, Md.: 1950) 168:3402–3411

103.

Hess PJ, Seeger JM, Huber TS et al (1997) Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. J Vasc Surg 26:113–118. doi:10.1016/S0741-5214(97)70154-X PubMed

104.

Engles RE, Huber TS, Zander DS et al (1997) Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 69:425–428. doi:10.1006/jsre.1997.5109 PubMed

105.

Byrne A, Reen DJ (2002) Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J Immunol (Baltimore, Md.: 1950) 168:1968–1977

106.

Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424–428. doi:10.1172/JCI116977 PubMed

107.

Finbloom DS, Winestock KD (1995) IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol (Baltimore, Md.: 1950) 155:1079–1090

108.

Clarke CJ, Hales A, Hunt A, Foxwell BM (1998) IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol 28:1719–1726. doi:10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO;2-QPubMed

109.

Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868–31874. doi:10.1074/jbc.274.45.31868 PubMed

110.

Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135:64–73. doi:10.1111/j.1365-2249.2004.02342.x PubMed

111.

Cassatella MA, Gasperini S, Bovolenta C et al (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94:2880–2889PubMed

112.

Ito S, Ansari P, Sakatsume M et al (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456–1463PubMed

113.

Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19:563–573. doi:10.1089/107999099313695 PubMed

114.

Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F (2002) Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol (Baltimore, Md.: 1950) 168:6404–6411

115.

Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8:240–246. doi:10.1038/nm0302-240 PubMed

116.

Pezzilli R, Billi P, Miniero R, Dig BB (1997) Serum interleukin-10 in human acute pancreatitis. Dis Sci 42:1469–1472. doi:10.1023/A:1018814710291

117.

Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174:1549–1555. doi:10.1084/jem.174.6.1549 PubMed

118.

Kwon OJ (1997) The role of nitric oxide in the immune response of tuberculosis Korean. Med Sci 12:481–487

119.

Gougerot-Podicalo MA, Elbim C, Chollet-Martin S (1996) Modulation by pro- and anti-inflammatory cytokines of the oxidative burst of human neutrophils. Pathol Biol (Paris) 44:36–41

120.

Dandona P, Mohanty P, Hamouda W, Aljada A, Kumbkarni Y, Garg R (1999) Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study. Clin Pharmacol Ther 66:58–65. doi:10.1016/S0009-9236(99)70054-8 PubMed

121.

Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA (1993) Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol (Baltimore, Md.: 1950) 151:5666–5674

122.

Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA (1995) Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (Baltimore, Md.: 1950) 154:4793–4802

123.

Gunnett CA, Heistad DD, Berg DJ, Faraci FM (2000) IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol 279:H1555–H1562PubMed

124.

Keel M, Ungethum U, Steckholzer E et al (1997) Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 90:3356–3363PubMed

125.

Adamopoulos S, Parissis JT, Paraskevaidis I et al (2003) Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 24:2186–2196. doi:10.1016/S0195-668X(03)00480-9 PubMed

126.

El Azab SR, Rosseel PM, de Lange JJ et al (2002) Dexamethasone decreases the pro- to anti inflammatory cytokine ratio during cardiac surgery. Br J Anaesth 88:496–501. doi:10.1093/bja/88.4.496 PubMed

127.

Giomarelli P, Scolletta S, Borrelli E, Biagioli B (2003) Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 76:117–123. doi:10.1016/S0003-4975(03)00194-2 PubMed

128.

Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (1995) IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96:2304–2310. doi:10.1172/JCI118286 PubMed

129.

Ksontini R, MacKay SL, Moldawer LL (1998) Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 133:558–567. doi:10.1001/archsurg.133.5.558 PubMed

130.

Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S (1994) Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179:1695–1699. doi:10.1084/jem.179.5.1695 PubMed

131.

Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL (1995) Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 95:2868–2876. doi:10.1172/JCI117993 PubMed

132.

Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM (1994) Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678–2683PubMed

133.

Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205–1208. doi:10.1084/jem.177.4.1205 PubMed

134.

Gerard C, Bruyns C, Marchant A et al (1993) Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547–550. doi:10.1084/jem.177.2.547 PubMed

135.

Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272:50–53. doi:10.1126/science.272.5258.50 PubMed

136.

Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138–146. doi:10.1016/0167-5699(96)80606-2 PubMed

137.

Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD (2003) Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci 105:45–50. doi:10.1042/CS20020359 PubMed

138.

Waehre T, Halvorsen B, Damas JK et al (2002) Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 32:803–810. doi:10.1046/j.1365-2362.2002.01069.x PubMed

139.

Lentsch AB, Shanley TP, Sarma V, Ward PA (1997) In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 15:2443–2448. doi:10.1172/JCI119786

140.

Shan K, Kurrelmeyer K, Seta Y et al (1997) The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 12:218–223. doi:10.1097/00001573-199705000-00002 PubMed

141.

Meldrum DR (1998) Tumor necrosis factor in the heart. Am J Physiol 274:R577–R595PubMed

142.

Mann DL (1996) The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. J Card Fail 2:S165–S172. doi:10.1016/S1071-9164(96)80073-X PubMed

143.

Kelly A, Lynch E, Vereker Y et al (2001) The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation. A role for JNK. J Biol Chem 276:45564–45572. doi:10.1074/jbc.M108757200 PubMed

Title: Biology of TNFα and IL-10, and their imbalance in heart failure
Authors: Kuljeet Kaur
Sanjiv Dhingra
Jan Slezak
Anita K. Sharma
Anju Bajaj
Pawan K. Singal
Publication date: 01-06-2009
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2009
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-008-9104-z

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Biology of TNFα and IL-10, and their imbalance in heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Hyponatremia in heart failure

Introduction: vasopressin therapy

Treatment options for hyponatremia in heart failure

Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design

Sleep disordered breathing in chronic heart failure

Hyponatremia in heart failure concluding remarks

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page